A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Epirubicin+Cyclophosphamide|DRUG: liposomal-doxorubicin+Cyclophosphamide
Sponsor: TTY Biopharm